We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Trial of Gabapentin in Vulvodynia: Biological Correlates of Response

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01301001
First Posted: February 23, 2011
Last Update Posted: November 8, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
University of Tennessee Health Science Center
Information provided by (Responsible Party):
University of Tennessee
May 13, 2010
February 23, 2011
August 28, 2017
November 8, 2017
November 8, 2017
August 2012
January 2016   (Final data collection date for primary outcome measure)
Tampon Test Pain Intensity [ Time Frame: Week 6 for each treatment arm ]
Tampon pain on a 11-point Numeric Rating Scale (0 = no pain at all; 10 = worse pain ever). One tampon was inserted each week. Tampon pain was assessed during last week of maintenance phase (7 days).
The primary outcome measure of this project are to test the prediction that pain from tampon insertion is lower in PVD patients when treated with gabapentin compared to when treated with placebo. [ Time Frame: 4 years ]
The immediate goal is to conduct a multicenter, randomized controlled trial (RCT) of gabapentin treatment for PVD, and which will also provide critical data on a new PVD-testing and response paradigm, as well as on characteristics that may define subtypes of PVD.
Complete list of historical versions of study NCT01301001 on ClinicalTrials.gov Archive Site
  • Coital Pain [ Time Frame: Week 6 of each treatment arm ]
    Coital pain on an 11-point Numeric Rating Scale (0 = no pain at all; 10 = worse pain ever), assessed after each sexual intercourse event. The number of sexual intercourse events was averaged during final week of each treatment arm.
  • Vulvodynia Pain [ Time Frame: Week 6 for each treatment arm ]
    Overall vulvodynia pain on an 11-point Numeric Rating Scale (0 = no pain at all; 10 = worse pain ever). Pain was assessed daily during the last week of treatment. Daily scores were averaged.
The secondary outcome measure is to perform a mechanism-based analysis of gabapentin effectiveness, and to gain insight into the underlying pathophysiology of subtypes of PVD that may lead to more specific treatment options. [ Time Frame: 4 years ]
The Long-range goals of this project are to explicate the underlying pathophysiologic mechanisms of PVD, and to use this knowledge to create evidence-based differential diagnoses of subtypes of PVD and to individualize treatments for each subtype.
Not Provided
Not Provided
 
A Trial of Gabapentin in Vulvodynia: Biological Correlates of Response
A Controlled Trial of Gabapentin in Vulvodynia: Biological Correlates of Response
The Specific aims of this project are to (1) test the prediction that pain from tampon insertion (primary outcome measure) is lower in PVD patients when treated with gabapentin compared to when treated with placebo. Secondary outcome measures include intercourse pain and 24-hour pain and (2)perform a mechanism-based analysis of gabapentin effectiveness, and to gain insight into the underlying pathophysiology of subtypes of PVD that may lead to more specific treatment options.
This is a 18-week, randomized, double-blind, placebo-controlled, two-treatment, two-period crossover design, where 120 women between 18 of age and older who report insertional dyspareunia, pain with tampon insertion, and tenderness localized to the vulvar vestibule will be enrolled in the study. Electronically entered daily diaries will be used to determine if pain is lower in PVD subjects when treated with gabapentin (up to 3600 mg/d) compared to when treated with placebo. Biological measurements will include assessment of allodynia and hyperalgesia from capsaicin administration, muscle tension using a vaginal pressure algometer, number of tender points by clinical examination, and changes in blood pressure, pulse and heart rate variability. . The Long-range goals of this project are to explicate the underlying pathophysiologic mechanisms of PVD, and to use this knowledge to create evidence-based differential diagnoses of subtypes of PVD and to individualize treatments for each subtype. The immediate goal is to conduct a multicenter, randomized controlled trial (RCT) of gabapentin treatment for PVD, and which will also provide critical data on a new PVD-testing and response paradigm, as well as on characteristics that may define subtypes of PVD. Gabapentin, an anticonvulsant with analgesic, anxiolytic, and antispasmotic effects, was selected because of its efficacy in treating other neuropathic pain conditions.
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Vulvodynia
  • Drug: Placebo oral capsule
    Placebo 2 capsules am and 3 capsules pm
    Other Name: Sugar pill
  • Drug: Gabapentin
    Gabapentin 1200 mg am and 1800 mg pm
    Other Name: Gralise 600 mg capsule
  • Placebo Comparator: Placebo oral capsule
    Placebo capsule daily in first intervention period and Gabapentin capsule 3000 mg daily in in second intervention (after washout period)
    Interventions:
    • Drug: Placebo oral capsule
    • Drug: Gabapentin
  • Active Comparator: Gabapentin
    Gabapentin capsule 3000 mg daily in first intervention period and Placebo capsule in second intervention (after washout period)
    Interventions:
    • Drug: Placebo oral capsule
    • Drug: Gabapentin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
230
January 2016
January 2016   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Women who are 18 years of age and older, as long as no vaginal atrophy is present. If vaginal atrophy is present, then topical hormone replacement can be provided for a minimum of 6 weeks and then she must be re-screened to be eligible,
  2. Greater than 3 continuous months of insertional (entryway) dyspareunia, pain to touch, or both with tampon insertion (modified 'Friedrich's Criteria', and
  3. an average pain level of "4" or greater on the 11-point tampon test (0 = no pain at all; 10 = worse pain ever) during the 2-week screening period must be exhibited.

(One tampon will be inserted each week). 4.) Must report pain with the "Tampon Insertion Pain" Test at visit 1

Exclusion Criteria:

  1. Other vulvar conditions, including dermatoses, vulvitis, vulvar papillomatosis, or atrophic vaginitis (presence of a maturation index)
  2. previous vestibulotomy
  3. active vaginal infection (positive Affirm ™ VPIII microbial identification test)
  4. pregnancy or at risk for pregnancy and not using a reliable birth control method for at least 3 months prior to entering the study
  5. any unstable medical condition, including renal impairment (creatinine clearance of ≤60 mL/min, BUN > 30mg/dL, serum creatinine > 2 mg/dL), significant hematological disease (leukopenia [WBC < 3.0 x 10-3µl, leukocytosis [WBC >20.0 x 10-3μl], neutropenia [ABS < 1.50 x 10-3 μl, <20%]), (thrombocytopenia [platelets < 100,000 μl], anemia [HCT < 27%, HBG <8 g/dL, RBC <3 x 10-6]), cardiovascular disease (cardiac conduction disturbance, CHF, hypertension [140/90]), hepatic insufficiency (serum AST, ALT, or ALP ≥ 3 times upper limit of normal), neurological disorder (seizures, syncopal episodes, peripheral neuropathy, severe pain other than that caused by vulvodynia), autoimmune disease, or respiratory illness
  6. psychiatric disorder, including history of major depressive disorder or substance abuse disorder within the past 6 months, a score of > 12 on the depression subscale of the Hospital Anxiety and Depression Scale (HADS), indicting a major depressive episode (35,36), a serious risk of suicide, or lifetime history of psychosis, hypomania or mania
  7. multiple allergies
  8. use of benzodiazepines, opiates, muscle relaxants, tricyclic antidepressants (TCAs), serotonin-norepinephrine reuptake inhibitors (SNRIs) or CNS stimulants (including methylphenidate, amphetamine dextroamphetamine) within 2 weeks of randomization and during the study
  9. use of certain herbal agents within 2 weeks of randomization and during the study, including ginkgo biloba, evening primrose, St. John's Wort, Valerian, kava kava)
  10. topical lidocaine use
  11. Subjects, who are diagnosed with coexisting vaginismus, fibromyalgia and/or interstitial cystitis, must have greater vulvar pain than their coexisting conditions or they will not be eligible for study participation
  12. Subject who have previously taken gabapentin or Lyrica but discontinued the medication due to side effects are not eligible
  13. Subjects with active infections (Candida, BV, trichomonas, chlamydia, GC and HSV via Affirm/culture) must be treated and re-screened to eligible for participation
  14. Subjects with 10% or greater parabasal cells and/or vaginal atrophy can be provided with topical hormone replacement for a minimum of 6 weeks and then must be re-screened to be eligible
  15. Subjects who have had gastric bypass surgery are ineligible for study participation due to drug absorption problems
  16. HPV/abnormal Pap is not exclusionary
  17. Ongoing counseling and/or physical therapy is not exclusionary
  18. Subjects who report signs of mixed Vulvodynia (spontaneous/provoked, localized, generalized) during prescreening will not be excluded
Sexes Eligible for Study: Female
18 Years and older   (Adult, Senior)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01301001
10-00985-FB CSBrown Vulvodynia
Yes
Not Provided
Plan to Share IPD: Undecided
University of Tennessee
University of Tennessee
University of Tennessee Health Science Center
Principal Investigator: Candace S Brown, MSN, PharmD University of Tennessee Health Science Center
Principal Investigator: David C Foster, M.D. University of Rochester School of Medicine and Dentistry
Principal Investigator: Gloria A Bachmann, M.D. Rutgers Robert Wood Johnson Medical School
University of Tennessee
April 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP